C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)

S. A. Pupyshev, L. V. Koukol, B. I. Geltzer, A. V. Pupyshev (Vladivostok, Russian Federation)

Source: Annual Congress 2005 - Respiratory disease management in primary care
Session: Respiratory disease management in primary care
Session type: Thematic Poster Session
Number: 3519
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. A. Pupyshev, L. V. Koukol, B. I. Geltzer, A. V. Pupyshev (Vladivostok, Russian Federation). C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP). Eur Respir J 2005; 26: Suppl. 49, 3519

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007


C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012


Diagnostic and prognostic value of C-reactive protein in community-acquired pneumonia hospitalized patients
Source: Eur Respir J 2004; 24: Suppl. 48, 188s
Year: 2004

Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP)
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016


Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007


The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004

C-reactive protein (C-RP) in patients with chronic heart failure (CHF) and community-acquired pneumonia (CAP): usefulness to guide antibiotic prescription
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018


Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia
Source: Eur Respir J 2008; 32: 726-732
Year: 2008



C-reactive protein in community-acquired pneumonia
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006


Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009

High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010


Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP)
Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment
Year: 2013


Predictive value of plasma D-dimer in patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010


Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients
Source: Annual Congress 2012 - Respiratory infections: a clinical point of view
Year: 2012


The influence of prednisolone on C-reactive protein and procalcitonin in patients hospitalised with community-acquired pneumonia
Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia
Year: 2010


Procalcitonin and C reactive protein as markers of treatment failure in community-acquired pneumonia
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006


Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008


C-reactive protein levels in community-acquired pneumonia
Source: Eur Respir J 2003; 21: 702-705
Year: 2003



Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 488s
Year: 2006